Exchange: NASDAQ·Updated 07:55 PM EST
RADX logo

RADX Radiopharm Theranostics Ltd - ADR

$0.6304
$0.0426
(6.33%)
Today
Closed $0.6304
$0.0174
(2.76%)
After Hours
Mkt Cap$9.9M
Vol12,988.00

About RADX

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company was founded by Paul A. Hopper in 2021 and is headquartered in Carlton, Australia.
36

Bearish Sentiment

How do you feel about RADX?

Lalalilala
$RADX This is just a decision-making aid, okay, but I asked five artificial intelligences this simple question: ==> Right now, do you think it's possible to see it back down to $3.50 by March 31, 2027, without a reverse split? Of course, and without any beating around the bush, all five answers were the same: NO. There you have it. Have a good week everyone. I'm starting to liquidate my position tomorrow at the opening. Good luck to those who are still there. I was completely wrong.
1
Manpreet00
$RADX if RAD101 specificity is lower than 80%, below are the complementary technologies that exist to improve diagnostic performance. Perfusion MRI (DSC/DCE) MR spectroscopy Amino acid PET
1
Lalalilala
$RADX , You left here (RADX) where you were posting about two or three extremely bullish messages three times a day. Suddenly, you left that office because I think you decided RADX had nothing good to offer shareholders. You went to CATX (which just collapsed by almost 50% in a few days), and I see that even there, despite the rout, you're still posting extremely bullish messages. I'm having a hard time understanding you... Will you switch to another stock when you decide $CATX has nothing good to offer shareholders? Where will you go next? Do you think many retail shareholders are being lulled into complacency by your messages? Seriously. Stop posting only to disappear a few days later when things don't go your way!
6
Pne01
$RADX is pleased to announce it has received $8,000,000 from Rockford Capital under a funding facility secured against Radiopharm’s anticipated FY26 Research and Development Tax Incentive (RDTI). The funds will support the clinical trial pipeline and otherwise for general working capital of the Company. The funding agreement with Rockford Capital provides Radiopharm with early access to a portion of the Company’s anticipated FY26 RDTI. The facility is secured against the anticipated FY26 RDTI to be received from the Australian Taxation Office, with interest charged at a commercial rate. Repayment is timed to follow the anticipated receipt of the Company’s FY26 RDTI, and is due by 26 October 2027. The facility can be repaid at any time without penalty prior to this date. The Australian Government RDTI program provides companies engaging in eligible activities with a refundable tax offset of up to 43.5%.
5
Rayvio_News_Filter
$RADX 🏥 Radiopharm Theranostics Limited reported interim Phase 2b imaging results for RAD101 in suspected recurrent brain metastases, showing 93.5% patient-level agreement with contrast-enhanced MRI, 85.7% preliminary sensitivity, and no serious treatment-emergent adverse events among 32 dosed participants. Market-relevant event
4
Ontherag
$RADX If FDA thinks are data is good for phase 3, I’m looking forward to the SNO presentation in 2 weeks
4
Pne01
$RADX “We are grateful to the FDA for its constructive review of our clinical data and for aligning with us on a single, multicenter pivotal study design. Importantly, the approximately 280-patient trial is substantially smaller than many historical registrational imaging studies (i.e. prostate cancer imaging agents required two Phase 3 trials and more than 700 patients combined.) We believe this reflects the significant unmet medical need faced by patients with brain metastases from solid tumors. We look forward to advancing RAD101 into this pivotal study as we work to provide physicians and patients with a more reliable tool to guide critical treatment decisions."
4
Lalalilala
$RADX We'll get through this! We might not make any money, no (depending on our individual cost prices), but we'll land on our feet, I'm pretty sure of it! Even if it takes another three or four months, I'm not budging, and I still haven't sold a single share. I'm avoiding looking at it too much to prevent myself from sinking psychologically. It's difficult, but we're hanging in there. Too late to sell. We should have sold on July 1st when we saw that the Phase 2B results hadn't been published!
3
Biotechs2027
For RAD101, I’d call 90% sensitivity and 90% specificity fantastic. That would mean it catches about 9 in 10 true recurrences while correctly identifying about 9 in 10 cases that are treatment effect or radiation necrosis $RADX
3
e17
$RADX These are just my thoughts but I believe a partnership for 30-100m will take place first with rad101 as a stepping stone ”try then buy” and when rad202 and rad204 mature with results a buy out for around 800m will take place bringing us to about $50. The company is actually doing everything perfectly as a disrupting technology they're just burning cash too fast and so the attention goes there first, but with a partnership intact that flips everything theyll have the cash to finish the trials no ss changes and investors will pour in for a buyout on this companies ground breaking therapies. 💪
3
Ontherag
$RADX At this point, take it as low as you want. They can’t reverse split because our share count is so low and offering at these levels are extremely toxic. Only way out is partnership.
2
Manpreet00
$RADX that Laila person should stay awya from the stock market. I have seen this play out multiple times. Institutions drag the share price down while the fundamentals improves or in this case the pipeline. Then when enough retailers exit on a pump boom
2
__LucidDreamer__
$RADX i was still way off. What a pos. Sunk cost at this point. Buyout/partnership or bust.
2
Ontherag
$RADX I found the SNO abstract - presentation on SaturdayAbstract. Distinguishing tumor progression (TP) from radiation necrosis (RN) after stereotactic radiosurgery or radiotherapy for brain metastases remains challenging because conventional imaging has limited specificity. 18F-RAD101 is a novel Positron Emission Tomography (PET) radioligand targeting short-chain fatty acid metabolism in brain metastases, with low uptake in normal brain tissue. This open-label, single-dose, single-arm, multicenter Phase 2b study (NCT06777433) evaluates 18F-RAD101 PET in participants with suspected recurrence of previously irradiated brain metastases.
2
twitofstock
$RADX strange that at the last 2 conferences participated only dr. Dimitris who is the chief medical officer, but Paul Hopper or Ricardo Canevari are absent, maybe they are truely busy with a partnership :/
1
Pne01
$RADX R&D Tax Incentive Received the 2025 financial year R&D tax refund of A$5,885,131 (including A$104,475 interest) in July 2026. Subsequent to 30 September 2026: Received A$8,000,000 from Rockford Capital under a funding facility secured against the anticipated FY26 Research and Development Tax Incentive (RDTI). Cash Position & Operating Cash Flow Closing cash: A$7.5 million at 30 September 2026 (up from A$4.1 million at the end of the prior quarter). Net cash outflows from operating activities: A$10.7 million. Direct R&D expenditure and staff costs accounted for 93% of operating expenditure for the quarter (excluding the R&D tax refund receipt). Other Subsequent to quarter-end, Radiopharm increased its ownership in Radiopharm Ventures from 87.5% to 93.75%. Payments to related parties (director fees) were made in the ordinary course of business at commercial rates.
1
Manpreet00
$RADX good. please go ahead and sell so we can finally start moving back up. Mind you, he will be back tomorrow with newly found optimism for RADX. The guy swings like a pendulum
twitofstock
$RADX at the end of september they had 7.46mill + 8 mill debt = 15.46mill total. Cash burn is 4.84mill per month. It means that by end of year, all the cash will be gone. If they dont find a partner this month than $RADX will be banckrupt by end of year. And the market price reflect this, im down now 85% since i took a position in this pos company, tragic
twitofstock
$RADX Unfortunately both the Deutsche bank conference and the SNO2026 didn't show any new info just same old data. We should expect another drop on monday :/
VetteAlpine
$RADX is someone aware that BNP paribas is detecting the 32% of the stake - probably from the latest spp? what do you think about?

Advertisement|Remove ads.